Oxybutynin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and TLV (Sweden) recommended or restricted oxybutynin, while CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 13.1 years separate the first record, 26 Jun 2013 at HAS (France), from the most recent, 7 Jul 2026 at AWMSG (Wales).
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for oxybutynin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 5 of 9 records date from 2023 or later.
Against its own class, oxybutynin is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class G04B average 74%.
3 distinct indication wordings are recorded for oxybutynin by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess oxybutynin, on 26 Jun 2013; AWMSG (Wales) did not open a file until 7 Jul 2026 — an unusually long tail of 13.1 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
2 of the 6 agencies here assessed oxybutynin more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for oxybutynin.
The full ledger for oxybutynin reads 2 not recommended, 2 other, 1 deferred to NICE and 1 terminated, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 7 May 2026 | NICE TA1154 | terminated appraisal | source |
| CIPM (Spain) | 26 Sep 2024 | Indicación terapéutica autorizada: Vesoxx está indicado para la inhibición de la hiperactividad neurogénica del detrusor… | not financed by the SNS · art. 92 d, e | source |
| PBAC (Australia) | 2023 | Detrusor overactivity in patients unable to tolerate or unable to swallow oral oxybutynin | Advice Provided | source |
| HAS (France) | 10 Apr 2019 | Listing renewal (Transparency Committee) | SMR low | source |
| TLV (Sweden) | 19 Jun 2018 | Oxybutynin Unimedic ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
4 further decisions for oxybutynin, across 3 agencies, are not shown here. They include the most recent record on file, 7 Jul 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- sildenafil — same ATC class G04B — Urologicals
- tadalafil — same ATC class G04B — Urologicals
- mirabegron — same ATC class G04B — Urologicals
- apomorphine — same ATC class G04B — Urologicals
- solifenacin — same ATC class G04B — Urologicals
- vibegron — same ATC class G04B — Urologicals
Coverage: 9 decisions for oxybutynin from 6 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class G04B — Urologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.